SCHEMBL1967596

SCHEMBL1967596

CN1CCC(c2ccc([N+](=O)[O-])cc2O)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.58
HIF1A Q16665 1/20 0.57
SLC18A3 Q16572 1/20 0.50
PKM P14618 1/20 0.48
CDK1 P06493 1/20 0.47
CDK4 P11802 1/20 0.47
PRKCA P17252 1/20 0.47
CDK2 P24941 1/20 0.47
GSK3A P49840 1/20 0.47
GSK3B P49841 1/20 0.47
ACHE P22303 1/20 0.47
GPR35 Q9HC97 2/20 0.46
HTR1A P08908 2/20 0.46
HTR1D P28221 2/20 0.46
HTR1B P28222 2/20 0.46
HTR1F P30939 2/20 0.46
SIRT6 Q8N6T7 2/20 0.45
QDPR P09417 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25882536 0.83 HSP90AA1 (0.47) HSP90AA1HIF1ASLC18A3PKMCDK1
SCHEMBL16904547 0.81 ACHE (0.46) HSP90AA1HIF1ASLC18A3PKMACHE
SCHEMBL2015540 0.81 HSP90AA1 (0.56) HSP90AA1HIF1ASLC18A3GPR35ALDH1A1
SCHEMBL27921572 0.80 ALDH1A1 (0.53) HSP90AA1HIF1ASLC18A3PKMACHE
SCHEMBL1531296 0.78 HSP90AA1 (0.84) HSP90AA1HIF1ASLC18A3GPR35ALDH1A1
SCHEMBL426360 0.76 SLC18A3 (0.58) SLC18A3CDK1CDK4PRKCACDK2
SCHEMBL3337136 0.76 APP (0.57) HTR1AHTR1DHTR1BHTR1F
SCHEMBL6640192 0.76 HTR1D (0.63) HTR1AHTR1DHTR1BHTR1F
SCHEMBL17368685 0.76 CYP1A2 (0.59) QDPR
SCHEMBL824173 0.75 GPR35 (0.50) SLC18A3PKMGPR35HTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
EP-2334301-B1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO SA (CH) 2018-02-14 EP disclosed
US-8815872-B2 Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH (DE) 2014-08-26 US disclosed
CN-102143750-B Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH 2014-04-02 CN disclosed
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-12-01 US disclosed
CN-102143750-A Macrocyclics pyrimidines as aurora kinase inhibitors MERCK PATENT GMBH 2011-08-03 CN disclosed
EP-2334301-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS Merck Serono SA (CH) 2011-06-22 EP disclosed
WO-2010028116-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF MITF, PRKDC, PRKACA HSP90AA1 2452/4885HIF1A 1265/4885SLC18A3 4530/4885
US-20110294801-A1 MACROCYCLICS PYRIMIDINES AS AURORA KINASE INHIBITORS AURKC, AURKA, AURKB HSP90AA1 2347/4885HIF1A 3945/4885SLC18A3 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.